|Tested species reactivity||Hamster, Human|
|Published species reactivity||Avian, Rat, Human, Mouse|
|Host / Isotype||Mouse / IgG1, kappa|
|Immunogen||Recombinant protein encoding N-terminal amino acids 301-407 (the bHLH/leucine zipper domain) of human SREBP-1|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Western Blot (WB)||1-2 µg/ml|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
MA5-11685 targets SREBP-1 in WB applications and shows reactivity with Hamster and Human samples.
The MA5-11685 immunogen is recombinant protein encoding N-terminal amino acids 301-407 (the bHLH/leucine zipper domain) of human SREBP-1.
SREBP-1 and -2 are transcription factors which participate in the control of cholesterol homeostasis. SREBPs proteins, which are attached to the endoplasmic reticulum and nuclear envelope, are proteolytically cleaved and thus activated in response to conditions of low cellular sterol. Upon activation of SREBP-1 or -2, an ~480-500 amino acid, N-terminal cleavage fragment of these proteins enters the nucleus and activates transcription of enzymes and other proteins required for cholesterol synthesis. SCA (SREBP-cleavage activity) and caspase-3 proteases cleave SREBPs. SREBP proteins containing point mutations at caspase-3 cleavage sites (Asp460 in SREBP-1 and Asp468 in SREBP-2) do not become cleaved following induction of apoptosis, suggesting that SREBPs may play some role in apoptotic processes.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
The epigenetic drug 5-azacytidine interferes with cholesterol and lipid metabolism.
MA5-11685 was used in western blot to study the DNA methylation-independent mechanism by which the epigenetic drug 5-azacytidine inhibits the expression of genes involved in cholesterol and lipid metabolism
|Poirier S,Samami S,Mamarbachi M,Demers A,Chang TY,Vance DE,Hatch GM,Mayer G||The Journal of biological chemistry (289:18736)||2014|
PPAR¿ activation attenuates hepatic steatosis in Ldlr-/- mice by enhanced fat oxidation, reduced lipogenesis, and improved insulin sensitivity.
MA5-11685 was used in western blot to study the roles of decreased lipogenesis, increased beta-oxidation and enhanced insulin-sensitivity in the mechanism by which PPAR-delta protects against hepatic steatosis in LDLR-deficient mice
|Bojic LA,Telford DE,Fullerton MD,Ford RJ,Sutherland BG,Edwards JY,Sawyez CG,Gros R,Kemp BE,Steinberg GR,Huff MW||Journal of lipid research (55:1254)||2014|
Effect of cholesterol on lipogenesis and VLDL-TG assembly and secretion in goose primary hepatocytes.
MA5-11685 was used in western blot to study lipogenesis and the assembly and secretion of VLDL-triglyceride in goose primary hepatocytes and the effects of different concentrations of cholesterol
|Han CC,Wang JW,Pan ZX,Tang H,Xiang SX,Wang J,Li L,Xu F,Wei SH||Molecular and cellular biochemistry (374:163)||2013|
Inhibition of intestinal bile acid transporter Slc10a2 improves triglyceride metabolism and normalizes elevated plasma glucose levels in mice.
MA5-11685 was used in western blot to study the beneficial changes in triglyceride metabolism and plasma glucose concentrations of ob/ob obese mice following inhibition of intestinal Slc10a2
|Lundåsen T,Andersson EM,Snaith M,Lindmark H,Lundberg J,Östlund-Lindqvist AM,Angelin B,Rudling M||PloS one (7:null)||2012|
The lipogenic transcription factor ChREBP dissociates hepatic steatosis from insulin resistance in mice and humans.
MA5-11685 was used in western blot to study the role of the lipogenic transcription factor ChREBP in hepatic steatosis and insulin resistance in humans and mice
|Benhamed F,Denechaud PD,Lemoine M,Robichon C,Moldes M,Bertrand-Michel J,Ratziu V,Serfaty L,Housset C,Capeau J,Girard J,Guillou H,Postic C||The Journal of clinical investigation (122:2176)||2012|
Glucose 6-phosphate, rather than xylulose 5-phosphate, is required for the activation of ChREBP in response to glucose in the liver.
MA5-11685 was used in western blot to study the role of glucose-6-phosphate as the glucose-signaling metabolite that activates ChREBP in response to hepatic glucose
|Dentin R,Tomas-Cobos L,Foufelle F,Leopold J,Girard J,Postic C,Ferré P||Journal of hepatology (56:199)||2012|
Distinct regulation of adiponutrin/PNPLA3 gene expression by the transcription factors ChREBP and SREBP1c in mouse and human hepatocytes.
MA5-11685 was used in western blot to study the differential roles of ChREBP and SREBP1c in regulating adiponutrin expression in mouse and human hepatocytes
|Dubuquoy C,Robichon C,Lasnier F,Langlois C,Dugail I,Foufelle F,Girard J,Burnol AF,Postic C,Moldes M||Journal of hepatology (55:145)||2011|
Species-specific dibutyl phthalate fetal testis endocrine disruption correlates with inhibition of SREBP2-dependent gene expression pathways.
MA5-11685 was used in western blot to study the mechanism for the phthalate-induced inhibition of fetal testis steroidogenesis
|Johnson KJ,McDowell EN,Viereck MP,Xia JQ||Toxicological sciences : an official journal of the Society of Toxicology (120:460)||2011|
The TRC8 ubiquitin ligase is sterol regulated and interacts with lipid and protein biosynthetic pathways.
MA5-11685 was used in western blot to study the role of sterol-regulated TRC8 ubiquitin ligase in regulation of lipid and protein biosynthetic pathways
|Lee JP,Brauweiler A,Rudolph M,Hooper JE,Drabkin HA,Gemmill RM||Molecular cancer research : MCR (8:93)||2010|
Hepatitis C virus proteins induce lipogenesis and defective triglyceride secretion in transgenic mice.
MA5-11685 was used in western blot to study defects in lipid metabolism in a mouse model expressing human hepatitis C
|Lerat H,Kammoun HL,Hainault I,Mérour E,Higgs MR,Callens C,Lemon SM,Foufelle F,Pawlotsky JM||The Journal of biological chemistry (284:33466)||2009|
GRP78 expression inhibits insulin and ER stress-induced SREBP-1c activation and reduces hepatic steatosis in mice.
MA5-11685 was used in western blot to investigate the involvement of endoplasmic reticulum stress in hepatic steatosis and insulin resistance in obese ob/ob mice
|Kammoun HL,Chabanon H,Hainault I,Luquet S,Magnan C,Koike T,Ferré P,Foufelle F||The Journal of clinical investigation (119:1201)||2009|
Regulation of energy substrate utilization and hepatic insulin sensitivity by phosphatidylcholine transfer protein/StarD2.
MA5-11685 was used in western blot to examine the role of phosphatidylcholine transfer protein/StarD2 in hepatic insulin sensitivity
|Scapa EF,Pocai A,Wu MK,Gutierrez-Juarez R,Glenz L,Kanno K,Li H,Biddinger S,Jelicks LA,Rossetti L,Cohen DE||FASEB journal : official publication of the Federation of American Societies for Experimental Biology (22:2579)||2008|
Liver-specific inhibition of ChREBP improves hepatic steatosis and insulin resistance in ob/ob mice.
MA5-11685 was used in western blot to study the beneficial effects of shRNA-mediated knockdown of ChREBP on hepatic steatosis and insulin sensitivity in ob/ob leptin-deficient mice
|Dentin R,Benhamed F,Hainault I,Fauveau V,Foufelle F,Dyck JR,Girard J,Postic C||Diabetes (55:2159)||2006|
Insulin regulation of glucokinase gene expression: evidence against a role for sterol regulatory element binding protein 1 in primary hepatocytes.
MA5-11685 was used in western blot to study the lack of SREBP-1 involvement in the regulation of glucokinase gene expression in primary hepatocytes
|Gregori C,Guillet-Deniau I,Girard J,Decaux JF,Pichard AL||FEBS letters (580:410)||2006|
Polyunsaturated fatty acids suppress glycolytic and lipogenic genes through the inhibition of ChREBP nuclear protein translocation.
MA5-11685 was used in western blot to study the mechanism by which polyunsaturated fatty acids suppress the expresson of genes involved in glycolysis and lipogenesis
|Dentin R,Benhamed F,Pégorier JP,Foufelle F,Viollet B,Vaulont S,Girard J,Postic C||The Journal of clinical investigation (115:2843)||2005|
Hepatic farnesyl diphosphate synthase expression is suppressed by polyunsaturated fatty acids.
MA5-11685 was used in western blot to study the mechanism by which polyunsaturated fatty acids suppress liver farnesyl diphosphate synthase expression
|Le Jossic-Corcos C,Gonthier C,Zaghini I,Logette E,Shechter I,Bournot P||The Biochemical journal (385:787)||2005|
Hepatic glucokinase is required for the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression.
MA5-11685 was used in western blot to study the role of hepatic glucokinase in the synergistic action of ChREBP and SREBP-1c on glycolytic and lipogenic gene expression
|Dentin R,Pégorier JP,Benhamed F,Foufelle F,Ferré P,Fauveau V,Magnuson MA,Girard J,Postic C||The Journal of biological chemistry (279:20314)||2004|
Evaluation of Fbxw7 expression and its correlation with expression of SREBP-1 in a mouse model of NAFLD.
MA5-11685 was used in immunohistochemistry to study the relationship between Fbxw7 and SREBP-1 in a murine model of non-alcoholic fatty liver disease
|Tu K,Zheng X,Yin G,Zan X,Yao Y,Liu Q||Molecular medicine reports (6:525)||2012|